- Home
- TRVG vs CHRS Comparison
TRVG vs CHRS Comparison
Compare TRVG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVG
- CHRS
- Stock Information
- Founded
- TRVG 2005
- CHRS 2010
- Country
- TRVG Germany
- CHRS United States
- Employees
- TRVG N/A
- CHRS N/A
- Industry
- TRVG EDP Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRVG Technology
- CHRS Health Care
- Exchange
- TRVG Nasdaq
- CHRS Nasdaq
- Market Cap
- TRVG 160.9M
- CHRS 191.3M
- IPO Year
- TRVG N/A
- CHRS 2014
- Fundamental
- Price
- TRVG $2.55
- CHRS $1.39
- Analyst Decision
- TRVG Buy
- CHRS Strong Buy
- Analyst Count
- TRVG 4
- CHRS 4
- Target Price
- TRVG $2.55
- CHRS $5.38
- AVG Volume (30 Days)
- TRVG 78.9K
- CHRS 2.0M
- Earning Date
- TRVG 02-04-2025
- CHRS 03-12-2025
- Dividend Yield
- TRVG N/A
- CHRS N/A
- EPS Growth
- TRVG N/A
- CHRS N/A
- EPS
- TRVG N/A
- CHRS N/A
- Revenue
- TRVG $510,563,239.00
- CHRS $304,340,000.00
- Revenue This Year
- TRVG N/A
- CHRS $2.47
- Revenue Next Year
- TRVG $6.00
- CHRS N/A
- P/E Ratio
- TRVG N/A
- CHRS N/A
- Revenue Growth
- TRVG N/A
- CHRS 44.19
- 52 Week Low
- TRVG $1.60
- CHRS $0.66
- 52 Week High
- TRVG $3.29
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- TRVG 61.11
- CHRS 45.86
- Support Level
- TRVG $2.23
- CHRS $1.38
- Resistance Level
- TRVG $2.88
- CHRS $1.60
- Average True Range (ATR)
- TRVG 0.17
- CHRS 0.13
- MACD
- TRVG 0.02
- CHRS -0.03
- Stochastic Oscillator
- TRVG 54.17
- CHRS 9.52
About TRVG trivago N.V.
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.